Spyre Therapeutics, Inc. (SYRE)
79.90
-0.20
(-0.25%)
USD |
NASDAQ |
Oct 16, 16:00
79.93
+0.03
(+0.04%)
After-Hours: 20:00
Spyre Therapeutics Research and Development Expense (Annual) : 171.65M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 171.65M |
| December 31, 2024 | 162.79M |
| December 31, 2023 | 84.04M |
| December 31, 2022 | 58.58M |
| December 31, 2021 | 57.07M |
| December 31, 2020 | 59.64M |
| Date | Value |
|---|---|
| December 31, 2019 | 64.60M |
| December 31, 2018 | 36.72M |
| December 31, 2017 | 22.82M |
| December 31, 2016 | 18.14M |
| December 31, 2015 | 11.45M |
| December 31, 2014 | 6.83M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie, Inc. | 8.249B |
| Incyte Corp. | 1.984B |
| SELLAS Life Sciences Group, Inc. | 16.02M |
| Relay Therapeutics, Inc. | 261.38M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |